HPDE was expected to show the “pure” phenotype of mutated GNAS, whereas the pancreatic cancer cells were expected to manifest the phenotype of mutated GNAS plus mutated KRAS (the latter corresponds to common mutations found in IPMN) [3], [4]. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.